Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 9/20 | 0.40 |
| ▸ | RCOR1 | Q9UKL0 | 6/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.40 |
| ▸ | LIG1 | P18858 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 2/20 | 0.35 |
| ▸ | HTR2B | P41595 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | RAD52 | P43351 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid Methyl Ester SCHEMBL28100928 | 0.84 | BRD4 (0.37) | KDM1ARCOR1KCNH2MAOBTSHR | |
| SCHEMBL3496985 | 0.84 | TSHR (0.43) | KDM1ARCOR1KCNH2MAOBTSHR | |
| SCHEMBL3496987 | 0.84 | TSHR (0.43) | KDM1ARCOR1KCNH2MAOBTSHR | |
| SCHEMBL5426053 | 0.84 | TSHR (0.43) | KDM1ARCOR1KCNH2MAOBTSHR | |
| SCHEMBL26086875 | 0.78 | TSHR (0.42) | KDM1ARCOR1KCNH2MAOBTSHR | |
| SCHEMBL25465635 | 0.77 | MAOB (0.47) | MAOBHTR2CHTR2BMAPTSMN1; SMN2 | |
| SCHEMBL22816597 | 0.77 | ESR2 (0.48) | — | |
| SCHEMBL31481064 | 0.77 | DDB1 (0.39) | MAOBMAPTTDP1MEN1KMT2A | |
| SCHEMBL1085761 | 0.76 | MAOB (0.43) | KDM1AMAOBMAPT | |
| SCHEMBL23148898 | 0.76 | HTR3A (0.38) | HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4087836-B1 | PROCESSES FOR PREPARING TRIAZOLE GLYCOLATE OXIDASE INHIBITORS | CANTERO THERAPEUTICS INC (US) | 2025-10-08 | — | — | EP | claimed |
| CN-114945559-B | Preparation method of triazole glycollic acid oxidase inhibitor | 坎特罗治疗有限公司 | 2025-03-11 | — | — | CN | claimed |
| WO-2024215907-A1 | CRYSTALLINE FORMS OF A 1H-1,2,3-TRIAZOLE-4-CARBOXYLIC ACID COMPOUND | Cantero Therapeutics, Inc. (US) | 2024-10-17 | — | — | WO | claimed |
| WO-2024212137-A1 | CRYSTALLINE FORMS OF A 1H-1, 2, 3-TRIAZOLE-4-CARBOXYLIC ACID COMPOUND | Cantero Therapeutics, Inc. (US) | 2024-10-17 | — | — | WO | claimed |
| US-20230129160-A1 | PROCESSES FOR PREPARING TRIAZOLE GLYCOLATE OXIDASE INHIBITORS | PHOENIX TISSUE REPAIR, INC. | 2023-04-27 | — | — | US | claimed |
| EP-4087836-A1 | PROCESSES FOR PREPARING TRIAZOLE GLYCOLATE OXIDASE INHIBITORS | Cantero Therapeutics, Inc. (US) | 2022-11-16 | — | — | EP | claimed |
| CN-114945559-A | Preparation method of triazole glycolate oxidase inhibitor | 坎特罗治疗有限公司 | 2022-08-26 | — | — | CN | claimed |
| US-20260132109-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2026-05-14 | — | — | US | disclosed |
| US-12503436-B2 | Compounds and compositions for treating conditions associated with STING activity | NOVARTIS PHARMA AG (CH) | 2025-12-23 | — | — | US | disclosed |
| EP-4087836-B1 | PROCESSES FOR PREPARING TRIAZOLE GLYCOLATE OXIDASE INHIBITORS | CANTERO THERAPEUTICS INC (US) | 2025-10-08 | — | — | EP | disclosed |
| CN-114945559-B | Preparation method of triazole glycollic acid oxidase inhibitor | 坎特罗治疗有限公司 | 2025-03-11 | — | — | CN | disclosed |
| CN-112399873-B | Triazole glycolate oxidase inhibitors | 坎特罗治疗有限公司 | 2024-10-25 | — | — | CN | disclosed |
| WO-2024212137-A1 | CRYSTALLINE FORMS OF A 1H-1, 2, 3-TRIAZOLE-4-CARBOXYLIC ACID COMPOUND | Cantero Therapeutics, Inc. (US) | 2024-10-17 | — | — | WO | disclosed |
| US-20100204119-A1 | 4-AMINO-5-OXO-7,8-DIHYDROPYRIMIDO[5,4-F][1,4]OXAZEPIN-6(5H)-YL PHENYL DERIVATIVES | PFIZER INC | 2010-08-12 | — | — | US | disclosed |
| US-20100204119-A1 | 4-AMINO-5-OXO-7,8-DIHYDROPYRIMIDO[5,4-F][1,4]OXAZEPIN-6(5H)-YL PHENYL DERIVATIVES | PFIZER INC | 2010-08-12 | — | — | US | disclosed |
| US-20100204119-A1 | 4-AMINO-5-OXO-7,8-DIHYDROPYRIMIDO[5,4-F][1,4]OXAZEPIN-6(5H)-YL PHENYL DERIVATIVES | PFIZER INC | 2010-08-12 | — | — | US | disclosed |
| WO-2010089686-A1 | 4-AMINO-7,8-DIHYDROPYRIDO[4,3-D]PYRIMIDIN-5(6H)-ONE DERIVATIVES | PFIZER INC. (US) | 2010-08-12 | — | — | WO | disclosed |
| WO-2010086820-A1 | 4-AMINO-5-OXO-7, 8-DIHYDROPYRIMIDO [5,4-F] [1,4] OXAZEPIN-6 (5H) -YL) PHENYL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | PFIZER INC. (US) | 2010-08-05 | — | — | WO | disclosed |
| WO-2010086820-A1 | 4-AMINO-5-OXO-7, 8-DIHYDROPYRIMIDO [5,4-F] [1,4] OXAZEPIN-6 (5H) -YL) PHENYL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | PFIZER INC. (US) | 2010-08-05 | — | — | WO | disclosed |
| US-20100197591-A1 | 4-AMINO-7,8-DIHYDROPYRIDO[4,3-d]PYRIMIDIN-5(6H)-ONE DERIVATIVES | PFIZER INC | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204119-A1 | 4-AMINO-5-OXO-7,8-DIHYDROPYRIMIDO[5,4-F][1,4]OXAZEPIN-6(5H)-YL PHENYL DERIVATIVES | DGAT1, DGAT2, MOGAT2 | KDM1A 1202/4885RCOR1 1646/4885KCNH2 2541/4885 |
| US-20100197591-A1 | 4-AMINO-7,8-DIHYDROPYRIDO[4,3-d]PYRIMIDIN-5(6H)-ONE DERIVATIVES | CDK7, DPYD, DHFR | KDM1A 2278/4885RCOR1 4325/4885KCNH2 607/4885 |
| US-20260132109-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, IRF3, CGAS | KDM1A 4356/4885RCOR1 2966/4885KCNH2 2189/4885 |
| US-12503436-B2 | Compounds and compositions for treating conditions associated with STING activity | STING1, CGAS, IRF3 | KDM1A 3640/4885RCOR1 2538/4885KCNH2 2622/4885 |
| US-20230129160-A1 | PROCESSES FOR PREPARING TRIAZOLE GLYCOLATE OXIDASE INHIBITORS | TH, AOX1, AOC3 | KDM1A 1941/4885RCOR1 4109/4885KCNH2 3464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.